Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease
K. Furuta (WakayamaCity, Japan), D. Fujimoto (WakayamaCity, Japan), A. Matsunashi (KobeCity, Japan), M. Tanaka (WakayamaCity, Japan), R. Shibaki (WakayamaCity, Japan), Y. Shimada (KobeCity, Japan), K. Nagata (KobeCity, Japan), K. Tomii (KobeCity, Japan), N. Yamamoto (WakayamaCity, Japan)
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Furuta (WakayamaCity, Japan), D. Fujimoto (WakayamaCity, Japan), A. Matsunashi (KobeCity, Japan), M. Tanaka (WakayamaCity, Japan), R. Shibaki (WakayamaCity, Japan), Y. Shimada (KobeCity, Japan), K. Nagata (KobeCity, Japan), K. Tomii (KobeCity, Japan), N. Yamamoto (WakayamaCity, Japan). Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease. 2241
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: